Sarepta Therapeutics | SRPT - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
BioCryst Pharmaceuticals USD -119.15M 268.74M 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Capricor Therapeutics USD 305.79M 221.92M 2025-12
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Esperion Therapeutics USD -301.96M 149.4M 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Incyte USD 5.17B 516.28M 2025-12
Insmed USD 738.98M 206.6M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
Moderna USD 8.65B 680M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novavax USD -127.75M 28.92M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 71.71B 1.55B 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Tectonic Therapeutic USD 251.33M 16.2M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12